Cipla stock: Healthy momentum in sales indicates strong earnings visibility

Cipla's relatively late entry into the US market is proving a blessing

Shares of Cipla are down 18 per cent from the highs of November but experts say this correction is an opportunity to accumulate the pharmaceutical major, for many reasons.

For one, its prospects in the world’s largest health care market, the US, remain firm, given the new products in the pipeline and the increase in new drug filings. Monday’s announcement of the launch of authorised generics of Aloxi, a drug used for treating chemotherapy-induced nausea and vomiting, is testimony. As the market size of the branded drug is estimated at $460 million a year, the launch of its generics through